Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis
NCT07130331 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-08-19
Summary
This study aimed to explore the efficacy and influencing factors of secukinumab in axSpA patients by conducting a real-world retrospective analysis.
Conditions
- Axial Spondylarthritis (axSpA)
- Secukinumab
Interventions
- DRUG
-
Secikinumab
secukinumab 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg s.c. every 4 weeks
Sponsors & Collaborators
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-06-01
- Primary Completion
- 2024-07-01
- Completion
- 2025-08-01
Countries
- China
Study Locations
More Related Trials
-
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
NCT02159053 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
NCT05303285 ·Status: RECRUITING ·Phase: PHASE4
-
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
NCT02896127 ·Status: COMPLETED ·Phase: PHASE3
-
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
NCT01358175 ·Status: COMPLETED ·Phase: PHASE3
-
The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
NCT05527444 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
NCT06905288 ·Status: RECRUITING
-
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
NCT02008916 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
NCT02721966 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
NCT01649375 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
NCT05206591 ·Status: WITHDRAWN ·Phase: PHASE3
-
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
NCT03136861 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA
NCT05242588 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis
NCT07339566 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
NCT03259074 ·Status: COMPLETED ·Phase: PHASE3
-
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
NCT03445845 ·Status: COMPLETED ·Phase: PHASE4
-
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
NCT02294227 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
NCT04285229 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
NCT05861102 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
NCT05467995 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
NCT06378697 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
NCT03129100 ·Status: COMPLETED ·Phase: PHASE3
-
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT06833112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
NCT03350815 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
NCT02404350 ·Status: COMPLETED ·Phase: PHASE3